

IFW

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	<b>Application Number</b>	10/718,517	
	<b>Filing Date</b>	November 24, 2003	
	<b>First Named Inventor</b>	Philip Seeman	
	<b>Group Art Unit</b>	3764	
	<b>Examiner Name</b>	N/A	
<b>Total Number of Pages in This Submission</b>	7	<b>Attorney Docket Number</b>	13459-3

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment / Response  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application)  <input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input type="checkbox"/> Other Enclosure(s) (please identify below):
<b>Remarks</b>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
<b>Firm or Individual name</b>	BERESKIN & PARR Patricia Power, Reg. No. 51,379
<b>Signature</b>	
<b>Date</b>	November 22, 2004

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <input type="text"/>			
<b>Typed or printed name</b>			
<b>Signature</b>		<b>Date</b>	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

November 22, 2004



Patricia Power B.Sc., Ph.D. (Chem.)  
416 957 1683 ppower@bereskinparr.com

Your Reference:  
Our Reference: 13459-3

## INFORMATION DISCLOSURE STATEMENT

The Commissioner of Patents  
& Trademarks  
Washington, D.C. 20231  
U.S.A.

Dear Sir:

**Re: U.S. Regular Patent Application No. 10/718,517**  
**Filed: November 24, 2003**  
**For: METHOD FOR TREATING ASPECTS OF ALCOHOLISM,**  
**ADDICTION AND PSYCHOSIS**  
**Inventors: Philip Seeman**

---

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, Applicants hereby submit an Information Disclosure Statement on Form PTO-1449 containing a listing of patents and other publications of which Applicant is aware. Applicants are also submitting the references listed on the Information Disclosure Statement.

All of the patents and publications submitted herewith are in the English language. Accordingly a concise explanation of the relevance of the documents is not required.

The Examiner is requested to indicate consideration of these documents by initialing the appropriate column.

Applicants reserve the right to contest the applicability of any of these documents as prior art against the subject application. If the Examiner has any questions concerning this Information Disclosure Statement, he/she is requested to contact the

*Please send all correspondence to the Mississauga office:*

2000 Argentia Rd., Plaza 4, Ste. 430,  
Mississauga, Ontario, Canada L5N 1W1  
Tel: 905.812.3600 Fax: 905.814.0031

Scotia Plaza, 40 King St. West, 40th Floor,  
Toronto, Ontario, Canada M5H 3Y2  
Tel: 416.364.7311 Fax: 416.361.1398


Waterloo Technology Campus, 408 Albert St., Ste. 2,  
Waterloo, Ontario, Canada N2L 3V3  
Tel: 519.783.3210 Fax: 519.783.3211

undersigned. Entry of the enclosed Information Disclosure Statement is believed to be in order and is respectfully requested.

This Information Disclosure Statement is being filed before the issuance of a first official action, and therefore no fees are required. However, please charge our deposit account No. 02-2095 if such a fee is required.

Respectfully submitted,

**PHILIP SEEMAN**

A handwritten signature in black ink, appearing to read 'P. Power', is written over a horizontal line.

Patricia Power

Registration No. 51,379

Dated: November 22, 2004

Bereskin & Parr  
Box 401, 40 King Street West  
Toronto, Ontario, Canada  
M5H 3Y2

(416) 364-7311

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	1	of	4
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	10/718,517
<b>Filing Date</b>	November 24, 2003
<b>First Named Inventor</b>	Philip Seeman
<b>Art Unit</b>	3764
<b>Examiner Name</b>	N/A
<b>Attorney Docket Number</b>	13459-3

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 4

**Complete if Known**

Application Number	10/718,517
Filing Date	November 24, 2003
First Named Inventor	Philip Seeman
Art Unit	3764
Examiner Name	N/A
Attorney Docket Number	13459-3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1.	SEEMAN, P. et al., "Alcohol-Withdrawn Animals Have a Prolonged Increase in Dopamine D2 <sup>High</sup> Receptors, Reversed by General Anesthesia: Relation to Relapse?", Synapse, 2004, pp. 77-83, Vol. 52.	
	2.	MAY, T., "Striatal Dopamine D <sub>1</sub> -Like Receptors Have Higher Affinity for Dopamine in Ethanol-Treated Rats", European Journal of Pharmacology, 1992, pp. 313-316, Vol. 215.	
	3.	HRUSKA, R. E., "Effect of Ethanol Administration on Striatal D <sub>1</sub> and D <sub>2</sub> Dopamine Receptors", Journal of Neurochemistry, 1988, 1929-1933, Vol. 50, No. 6.	
	4.	ROSSETTI, Z. L., "Marked Inhibition of Mesolimbic Dopamine Release: A Common Feature of Ethanol, Morphine, Cocaine and Amphetamine Abstinence in Rats", European Journal of Pharmacology, 1992, pp. 227-234, Vol. 221.	
	5.	VASCONCELOS, S. M. M. et al., "Effect of One-Week Ethanol Treatment on Monoamine Levels and Dopaminergic Receptors in Rat Striatum", Brazilian Journal of Medical and Biological Research, 2003, pp. 503-509, Vol. 36, No. 4.	
	6.	TABAKOFF, B. et al., "Development of Functional Dependence on Ethanol in Dopaminergic Systems", Journal of Pharmacology and Experimental Therapeutics, 1979, pp. 216-222, Vol. 208, No. 2.	
	7.	MIROVSKY, Y. et al., "Simultaneous Changes in Striatal Dopamine, Serotonin, and Metabolites After Withdrawal Seizures in Rats from dependence on Alcohol", Elsevier Science Direct, 1995, pp. 251-256, Vol. 12, No. 3.	
	8.	TAJUDDIN, N. F. et al., "Effects of Chronic Alcohol Consumption and Aging on Dopamine D2 Receptors in Fischer 344 Rats", Alcohol Clin. Exp. Res., 1996, pp. 144-151, Vol. 20, No. 1.	
	9.	HAMDI, A. et al. "Bidirectional Changes in Striatal D2-Dopamine Receptor Density During Chronic Ethanol Intake", Alcohol, 1992, pp. 133-137, Vol. 9, No. 2.	
	10.	KIM, M. O. et al., "Prolonged Ethanol Intake Increases D2 Dopamine Receptor Expression in the Rat Brain", Mol. Cells, 1997, pp. 682-687, Vol. 7, No. 5.	
	11.	THIELEN, R. J. et al., "Ethanol Drinking and Deprivation Alter Dopaminergic and Serotonergic Function in the Nucleus Accumbens of Alcohol-Preferring Rats", The Journal of Pharmacology and experimental Therapeutics, 2004, pp. 216-225, Vol 309.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				<i>Application Number</i>	10/718,517
				<i>Filing Date</i>	November 24, 2003
				<i>First Named Inventor</i>	Philip Seeman
				<i>Art Unit</i>	3764
				<i>Examiner Name</i>	N/A
Sheet	3	of	4	<i>Attorney Docket Number</i>	13459-3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	12.	BAILEY, C. P. et al., "Alterations in Mesolimbic Dopamine Function During the Abstinence Period Following Chronic Ethanol Consumption", <i>Neuropharmacology</i> , 2001, pp. 989-999, Vol. 41.	
	13.	DJOUMA, El et al., "The Effect of Chronic Ethanol Consumption and Withdrawal on $\mu$ -Opioid and dopamine D <sub>1</sub> and D <sub>2</sub> receptor density in Fawn-Hooded Rat Brain", <i>The Journal of Pharmacology and Therapeutics</i> , 2002, pp. 551-559, Vol. 302, No. 2.	
	14.	EBERT, D. et al., "Different Striatal Dopamine D2 Receptor Occupancy in Alcohol Dependent Patients with or without Physical Withdrawal Symptoms – A Study Using IBZM-SPECT", <i>Journal of Neural Transmission</i> , 2002, pp. 1215-1219, Vol. 109.	
	15.	PHILLIPS, T. J. et al., "Alcohol Preference and Sensitivity are Markedly reduced in Mice Lacking Dopamine D <sub>2</sub> Receptors", <i>Nature Neuroscience</i> , 1998, pp.610-615, Vol. 1, No. 7.	
	16.	FUCHS, V. et al., "The Effect of Ethanol and Haloperidol on Dopamine receptor (D2) Density", <i>Neuropharmacology</i> , 1987, pp. 1231-1233, Vol. 26, No. 8.	
	17.	ENGEL, J. et al., "The Effect of Long-Term Ethanol Treatment on the Sensitivity of the Dopamine Receptors in the Nucleus Accumbens", <i>Psychopharmacology</i> , 1976, pp. 253-257, Vol. 49.	
	18.	POHORECKY, L. A. et al., "Effect of Ethanol on Dopamine Synthesis in Rat Striatal Synaptosomes", <i>Drug and Alcohol Dependence</i> , 1977, pp. 329-334, Vol. 2.	
	19.	SAMOCHOWIEC, J. et al., "The Role of Dopamine Neurotransmission in Ethanol Dependence Development and Ethanol Withdrawal in Rats", <i>Pharmazie</i> , 1995, pp. 815-818, Vol. 50.	
	20.	VEKSHINA, N. L., "The Properties of the Brain Dopamine and GABA Receptors in Rats with Chronic Alcoholic Intoxication with Different ethanol Withdrawal Times", <i>Eksp. Klin. Farmakol.</i> , 1992, pp. 65-67, Vol. 55, No. 3.	
	21.	GILI-MARTÍN, E. et al., "Effects of Chronic Ethanol Treatment and Ethanol Withdrawal on [ <sup>3</sup> H]SCH23390 Binding to Rat Striatal Membranes", <i>Neuropharmacology</i> , 1997, pp. 101-106, Vol. 36, No. 1.	
	22.	HAMDJ, A. et al., "Bidirectional Changes in Striatal D1-Dopamine receptor Density During Chronic Ethanol Intake", <i>Life Sciences</i> , 1992, pp. 251-257, Vol. 52.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

4

**Complete if Known**

Application Number	10/718,517
Filing Date	November 24, 2003
First Named Inventor	Philip Seeman
Art Unit	3764
Examiner Name	N/A
Attorney Docket Number	13459-3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	23.	LUCCHI, L. et al., "Effect of Chronic Ethanol Treatment on Dopamine Receptor Subtypes in Rat Striatum", Brain Research, 1988, pp. 347-351, Vol. 449.	
	24.	RABIN, R. A. et al., "Effects of Ethanol Administration and Withdrawal on neurotransmitter Receptor Systems in C57 Mice", The Journal of Pharmacology and Experimental Therapeutics, 1980, pp.491-496, Vol. 213, No. 3.	
	25.	MAY, T. et al., "Striatal Dopamine Receptors and Adenylyl Cyclase Activity in a Rat Model of Alcohol Addiction: Effects of Ethanol and Lisuride Treatment", The Journal of Pharmacology and Experimental Therapeutics, 1995, pp. 1195-1203, Vol. 275, No. 3.	
	26.	WOODS, J. M. et al., "Effects of Chronic Alcohol Consumption and Aging on Dopamine D1 Receptors in Fischer 344 Rats", Alcohol Clin. Exp. Res., 1995, pp. 1331-1337, Vol. 19, No. 5.	
	27.	ROSSETTI, Z. L. et al., "Lack of Tolerance to Ethanol-Induced Dopamine Release in the rat Ventral Striatum", European Journal of Pharmacology, 1993, pp. 203-207, Vol. 231.	
	28.	GILI-MARTIN, E. et al., "Effect of Chronic treatment with Ethanol and Withdrawal of Ethanol on Binding of [ <sup>3</sup> H]SCH23390 to D1 Dopamine receptor in rat Visual Cortex and Hippocampus. An Autoradiographic Study", Neuropharmacology, 1994, pp. 1203-1209, Vol. 33, No. 10.	
	29.	ROMMELSPACHER, H. et al., "Adaptive changes of dopamine-D2 receptors in rat brain following ethanol withdrawal: a quantity autoradiographic investigation", Alcohol, 1992, pp. 355-362, Vol. 9 No. 5.	
	30.	HIETALA, J. et al., "Ethanol administration does not alter dopamine D1 and D2 receptor characteristics in rat brain", Neurosci. Lett., 1990, pp., 289-294, Vol. 108, No. 3.	
	31.	SEEMAN, P. et al., "Anesthetics Inhibit High-Affinity States of Dopamine D2 and Other G-Linked Receptors", Synapse, 2003, pp. 35-40, Vol. 50.	
	32.	SEEMAN, P. et al., "Amphetamine-Sensitized Animals Show a Marked Increase in Dopamine D <sub>2</sub> High Receptors Occupied by Endogenous Dopamine, Even in the Absence of Acute Challenges", Synapse, 2002, pp. 235-239, Vol. 46.	
	33.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.